Sustainable purification of gene therapy pharmaceuticals
| Reference number | |
| Coordinator | Nyctea Technologies AB |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | August 2024 - July 2025 |
| Status | Completed |
| Venture | Strategic efforts HI |
| Call | Sustainable manufacturing of pharmaceuticals and medical technology products - spring 2024 |
Important results from the project
The goal of the project was to validate a new technology for the purification of pharmaceuticals. Within the framework of the project, we succeeded in demonstrating a water-based electrochemical purification process that reduces the need for chemicals and solvents. The results indicate that the desired purity and yield can be achieved. Work remains before the technology is ready for implementation; for example, further scalability needs to be demonstrated.
Expected long term effects
The project is expected to contribute in the long term to reducing the considerable costs, both economic and environmental, associated with the industrial production of modern biological medicines such as gene therapies. More efficient production could have a direct impact on the availability of advanced treatments to significantly more patients around the world, directly contributing to the UN´s global objective for good health and well-being and supports the goals for sustainable production.
Approach and implementation
The operational work was carried out mainly by Nyctea Technologies at BioVentureHub in close collaboration with AstraZeneca, who provided access to materials and infrastructure for the validation. We were able to set a clear specification of the criteria that the technology needs to achieve for industrial adoption. The project followed the schedule well and the necessary resources were available. The collaboration has worked very well, but the ambition was set high and further work remains.